samedan logo
 
 
 
spacer
home > pmps > autumn 2020 > the future of the pharma ecosystem post-covid-19
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future of the Pharma Ecosystem Post-COVID-19

The ongoing global pandemic has caused complete upheaval across the world for individuals and businesses alike. Within the pharmaceutical and life science industry, the need to develop a vaccine quickly is putting immense pressure on a workforce that is arguably already stretched, as skills shortages continue to have an effect on resources. However, while the pandemic has certainly presented a number of challenges, it has also created opportunities that have the potential to help alleviate many long-standing recruitment barriers.

So, what impact has COVID-19 had on talent acquisition across the life science and pharma industry?

A Changing Talent Landscape

STEM skills shortages have been widely discussed for some time now, and anyone in the pharma or life science arena will certainly be acutely aware of the talent challenges facing almost every firm in the field. The simple truth is that following a career in STEM-related professions doesn’t appeal to enough individuals in education to ensure a steady stream of newly trained recruits to meet demand on a global scale. With digital skills in limited supply, but high demand across almost every sector, attracting tech talent into pharma and the life science industry isn’t easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jim Sykes has 20 years’ experience in talent acquisition and holds significant international experience, having supported clients and managed teams on a global basis. He is responsible for client relationships and delivery within the pharma and life science sector and the professional and business services sector at Alexander Mann Solutions.
spacer
Jim Sykes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

GlycoSeLect and IonDx Inc., Collaborating on High-throughput Glycoprotein Analyses

GlycoSeLect Ltd and IonDx Inc., are actively engaged in a research collaboration to evaluate the use of Recombinant Prokaryotic Lectins RPLs and IonDx’s Ion Mobility Spectrometry technology as a new way to screen glycoproteins rapidly. “GlycoSeLect’s glycan specific lectins provide a high degree of specificity that will improve detection, monitoring and profiling of glycosylation within a wide range of biotherapeutics. Hence, we are excited to join GlycoSeLect and apply our ion mobility technology to all phases of biotherapeutic production and help manufacturers streamline this analytical bottleneck”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx Inc.,
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement